Enliven Therapeutics (ELVN) is back in focus after a cluster of analyst rating confirmations linked to Merck’s supportive comments on similar therapies, following the company’s recent first quarter update and clinical progress on ELVN-001.

At a share price of $40.75, Enliven’s recent moves reflect a sharp year to date share price return of 162.23% and a 114.36% one year total shareholder return, even after a 10.08% share price pullback over the past 30 days. This suggests momentum has cooled in the short term as investors weigh fresh earnings and the Phase 3 plans against earlier enthusiasm.

If you are watching how sentiment around oncology and biotech shifts, it can be useful to see what else is moving and compare Enliven with 34 healthcare AI stocks

With Enliven now trading at $40.75 and a market cap of about $2.48b, recent returns and analyst targets suggest growing expectations. The real question is whether the current price leaves any upside the market has not already priced in.

Preferred Price to Book Multiple of 5.5x: Is it justified?

Analysts see room for upside from $40.75, but on a simple yardstick Enliven already trades at a P/B of 5.5x, which is well above the broader pharmaceuticals sector.

The price to book ratio compares the company’s market value to its net assets on the balance sheet. This is a common reference point for early stage biopharma where there is no revenue and the focus is on cash and research assets. For Enliven, the current 5.5x P/B aligns with its peer group average of 5.5x, suggesting investors are valuing it similarly to other companies at a comparable stage.

Where Enliven stands out is against the wider US Pharmaceuticals industry, where the average P/B is 2.7x. That is a clear premium, which implies investors are assigning a higher value to its pipeline and potential than the typical company in the sector. Whether that premium feels comfortable will come down to how you weigh its clinical progress, unprofitable status, lack of current revenue and the analyst consensus that earnings are expected to decline on average over the next three years.

Result: Price to book ratio of 5.5x (ABOUT RIGHT).

However, there are clear risks, including Enliven’s lack of current revenue, ongoing net loss of $98.777m, and the possibility that Phase 1 assets progress more slowly than hoped.

Next Steps

Sentiment around Enliven is mixed, with clear risks on one side and potential rewards on the other. Act quickly to review the numbers and shape your own view by weighing its 1 key reward and 5 important warning signs through the 1 key reward and 5 important warning signs

Ready for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use structured stock lists to quickly uncover fresh, data backed ideas tailored to your goals.

• Target resilience by reviewing companies in the 71 resilient stocks with low risk scores that aim for steadier performance when conditions change.
• Hunt for potential mispricing with the 49 high quality undervalued stocks that focuses on quality businesses trading below what their fundamentals might suggest.
• Strengthen your income and capital base with the solid balance sheet and fundamentals stocks screener (44 results) to spot stocks combining dependable financial footing with attractive yields.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.